Corneal Versus Conjunctival Delivery Using a Delivery Device

Phase 2

Withdrawn

• Conditions: Ocular Hypertension; Glaucoma, Open-Angle

• Registration Number: NCT00143429
• Lead Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Brief Summary

Compare the antihypertensive efficacy of three methods for installing Xalatan

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-09-01
• Study First Submitted QC: 2005-09-01
• Study First Posted: 2005-09-02
• Status Verified: 2015-03
• Last Update Submitted: 2021-02-01
• Last Update Posted: 2021-02-02

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria

• History of closed/barely open anterior chamber angle or a history of angle closure

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
IOP level in the study eye

Secondary Outcome Measures

Name	Time	Method
Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period